NasdaqGM . Currency in USD
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev CloseN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52wk Rangeundefined - undefined
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
Avg Vol (3m)N/A
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • 24/7 Wall St.2 years ago

    Is Ambit Biosciences Getting Enough in Its Buyout?

    Ambit Biosciences has announced that it is entering into a merger with Daiichi Sankyo in a deal worth up to $410 million.

  • Reuters2 years ago

    Japan's Daiichi Sankyo to acquire US biopharma Ambit Biosciences

    Japanese drugmaker Daiichi Sankyo Co Ltd has agreed to acquire U.S. The companies said in a joint statement that Daiichi Sankyo would acquire all outstanding common stock of San Diego-based Ambit Biosciences for $15 per share in cash through a tender offer, or about $315 million, and merge it with a subsidiary of Daiichi Sankyo. Ambit Biosciences shareholders will also be eligible for an additional cash payment if certain milestones are reached, which would bring the total transaction to $410 million on a fully diluted basis, they said.

  • Seeking Alpha2 years ago

    Over-Skepticism: 3 Biotech Companies Trading Too Close To Their Cash

    The recent sell-off in the biotech sector didn't leave any company unscathed - big or small, they all toppled, some more than others. The risk/reward ratio in the biotech sector was reshuffled, and new, ...